We estimate that the CEO of ANAPTYSBIO, INC ($ANAB), Daniel Faga, received a compensation of $6,133,943 in 2025. This is a decrease of -122.21% from an estimated $13,630,292 in 2024.
These estimates are based on a new DEF14A filing, filed with the SEC on June 29, 2026. Note that parsing errors may occur.
You can track $ANAB on Quiver Quantitative's $ANAB stock dashboard.
$ANAB Stock Insider Trading Activity
$ANAB Stock insiders have traded $ANAB stock on the open market 31 times in the past 6 months. Of those trades, 0 have been purchases and 31 have been sales.
Here’s a breakdown of recent trading of $ANAB stock by insiders over the last 6 months:
- DANIEL FAGA (President, CEO) has made 0 purchases and 13 sales selling 56,471 shares for an estimated $2,805,071.
- ERIC J LOUMEAU (CHIEF LEGAL OFFICER) has made 0 purchases and 7 sales selling 24,832 shares for an estimated $1,207,053.
- JOHN P. SCHMID has made 0 purchases and 3 sales selling 20,645 shares for an estimated $1,158,451.
- MAGDA MARQUET has made 0 purchases and 2 sales selling 11,000 shares for an estimated $530,531.
- PAUL F. LIZZUL (Chief Medical Officer) has made 0 purchases and 3 sales selling 10,104 shares for an estimated $446,526.
- DENNIS MULROY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 3 sales selling 7,786 shares for an estimated $343,998.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ANAB Stock Hedge Fund Activity
We have seen 104 institutional investors add shares of $ANAB Stock stock to their portfolio, and 106 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 1,877,587 shares (-97.1%) from their portfolio in Q1 2026, for an estimated $104,130,975
- ASSENAGON ASSET MANAGEMENT S.A. removed 839,934 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $40,720,000
- AFFINITY ASSET ADVISORS, LLC added 495,308 shares (+111.4%) to their portfolio in Q1 2026, for an estimated $27,469,781
- FMR LLC added 445,596 shares (+1643.8%) to their portfolio in Q1 2026, for an estimated $24,712,754
- BANK OF AMERICA CORP /DE/ added 370,319 shares (+283.2%) to their portfolio in Q1 2026, for an estimated $20,537,891
- MILLENNIUM MANAGEMENT LLC removed 337,999 shares (-41.5%) from their portfolio in Q1 2026, for an estimated $18,745,424
- D. E. SHAW & CO., INC. added 320,928 shares (+91.9%) to their portfolio in Q4 2025, for an estimated $15,558,589
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ANAB Stock Analyst Ratings
Wall Street analysts have issued reports on $ANAB in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/10/2026
- Barclays issued a "Overweight" rating on 01/20/2026
- UBS issued a "Buy" rating on 01/07/2026
To track analyst ratings and price targets for $ANAB Stock, check out Quiver Quantitative's $ANAB forecast page.
$ANAB Stock Price Targets
Multiple analysts have issued price targets for $ANAB recently. We have seen 9 analysts offer price targets for $ANAB in the last 6 months, with a median target of $76.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $95.0 on 06/10/2026
- Etzer Darout from Barclays set a target price of $75.0 on 05/13/2026
- Michael Yee from UBS set a target price of $76.0 on 05/13/2026
- Yasmeen Rahimi from Piper Sandler set a target price of $93.0 on 05/04/2026
- David Risinger from Leerink Partners set a target price of $85.0 on 04/28/2026
- Martin Fan from Wedbush set a target price of $75.0 on 03/12/2026
- John Lee from Truist Securities set a target price of $50.0 on 03/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
